Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

Shares of Moderna MRNA rose nearly 16% yesterday after a couple of SEC filings showed that two board members bought shares on ...

As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...

The leader of an iconic apparel company and the co-founder and chair of Moderna are the honored speakers for the Worcester ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

In an early clinical trial, an experimental norovirus vaccine given as a pill produced defensive responses exactly where it counts—in the saliva of older people most vulnerable to the explosive ...

Moderna, Inc. (NASDAQ:MRNA) shares rose for a second day on Wednesday, adding 15.94 percent to finish at $35.21 apiece as ...

Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...

A team has found two antibodies that can work together to neutralize the virus that causes COVID-19 in all its current known variations in a laboratory environment. More research is needed, but the ...

A big legal victory across the Atlantic Ocean was the news propelling Moderna (NASDAQ: MRNA) stock to a significant price ...

Now that Novavax has been added to the revamped COVID vaccines, you'll want to make sure to check on the changes to cost and more.